The new vaccine offers a potential breakthrough against a disease whose fatality rate is estimated to be between 40 per cent and 75 per cent

The study, published in The Journal of Pediatrics, showed that the aluminum used as vaccine adjuvants also does not increase the risk of the neurological condition